Published in Ann Surg on February 01, 2012
Outcomes of Cytoreductive Surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years; survival benefit at considerable morbidity and mortality. Ann Surg Oncol (2013) 1.19
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality. J Gastrointest Oncol (2016) 0.95
Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a single institution in Japan. Gastroenterol Res Pract (2012) 0.89
Outcomes of repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy. J Am Coll Surg (2012) 0.84
Patient- and surgeon-adjusted control charts for monitoring performance. BMJ Open (2014) 0.82
Preliminary Experience and Morbidity Analysis of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) from a Tertiary Cancer Center in India. J Clin Diagn Res (2015) 0.79
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol (2016) 0.77
Implementation of a standardized HIPEC protocol improves outcome for peritoneal malignancy. World J Surg (2015) 0.77
Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives. Curr Oncol (2016) 0.76
Impact of surgical volume of centers on post-operative outcomes from cytoreductive surgery and hyperthermic intra-peritoneal chemoperfusion. J Gastrointest Oncol (2016) 0.76
Intraperitoneal free cancer cells in gastric cancer: pathology of peritoneal carcinomatosis and rationale for intraperitoneal chemotherapy/hyperthermic intraperitoneal chemotherapy in gastric cancer. Transl Gastroenterol Hepatol (2016) 0.75
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colorectal cancer with peritoneal carcinomatosis: Clinical outcomes at 2 tertiary referral centers in Korea. Medicine (Baltimore) (2017) 0.75
High-quality results of cytoreductive surgery and heated intraperitoneal chemotherapy perfusion for carcinomatosis at a low volume institution. J Surg Oncol (2015) 0.75
Safe temperature range for intraoperative and early postoperative continuous hyperthermic intraperitoneal perfusion in a swine model of experimental distal gastrectomy with Billroth II reconstruction. J Transl Med (2013) 0.75
Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis. Medicine (Baltimore) (2016) 0.75
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified? Clin Transl Oncol (2017) 0.75
Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol (2012) 5.06
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol (2009) 3.04
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol (2011) 2.35
Preoperative chemoradiation in patients with resectable rectal cancer: results on tumor response. Ann Surg Oncol (2002) 1.97
Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol (2007) 1.56
Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol (2004) 1.51
Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity. Ann Surg Oncol (2007) 1.46
Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol (2008) 1.41
Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol (2009) 1.38
Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol (2008) 1.28
Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J Surg Oncol (2008) 1.12
Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol (2006) 1.12
Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. J Surg Oncol (2008) 1.10
Pathophysiology and biology of peritoneal carcinomatosis. World J Gastrointest Oncol (2010) 1.07
Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Gastrointest Oncol (2010) 1.05
A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer (2010) 1.05
Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg (2009) 1.03
Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol (2007) 1.03
Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. Clin Cancer Res (2008) 1.02
Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol (2008) 1.01
The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol (2014) 1.00
Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? Ann Surg Oncol (2010) 0.98
Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. J Surg Oncol (2008) 0.98
Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol (2007) 0.98
Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion. Ann Surg Oncol (2005) 0.95
Colobronchial fistula: an unusual complication after peritonectomy and hyperthermic intra-peritoneal chemotherapy (HIPEC). In Vivo (2009) 0.95
Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol (2003) 0.95
Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol (2006) 0.94
The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis. Ann Surg Oncol (2014) 0.93
The consensus statement on the locoregional treatment of abdominal sarcomatosis. J Surg Oncol (2008) 0.91
Consensus statement on peritoneal mesothelioma. J Surg Oncol (2008) 0.90
Learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies: analysis of two centres. J Surg Oncol (2012) 0.89
Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. Cancer (2005) 0.89
Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer (2013) 0.88
Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol (2008) 0.88
Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. Eur J Cancer (2010) 0.86
The eligibility for local-regional treatment of peritoneal surface malignancy. J Surg Oncol (2008) 0.85
Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study. Melanoma Res (2003) 0.85
Identification of a subgroup of patients at highest risk for complications after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg (2012) 0.84
Postoperative residual disease evaluation in the locoregional treatment of peritoneal surface malignancy. J Surg Oncol (2008) 0.84
Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research. J Surg Oncol (2011) 0.84
American Society of Peritoneal Surface Malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer. J Surg Oncol (2014) 0.84
Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma. Am J Surg (2002) 0.83
The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol (2013) 0.83
Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. Ann Surg Oncol (2006) 0.82
Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol (2012) 0.81
Experience with peritoneal mesothelioma at the Milan National Cancer Institute. World J Gastrointest Oncol (2010) 0.81
Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol (2009) 0.81
The importance of the learning curve and surveillance of surgical performance in peritoneal surface malignancy programs. Surg Oncol Clin N Am (2012) 0.81
Incidence of postoperative pancreatic fistula and hyperamylasemia after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol (2007) 0.80
Technical aspects of cytoreductive surgery. J Surg Oncol (2008) 0.79
Prevention and early treatment of peritoneal metastases from colorectal cancer: second-look laparotomy or prophylactic HIPEC? J Surg Oncol (2014) 0.79
The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4-6, 2006): methodology of disease-specific consensus. J Surg Oncol (2008) 0.79
The Delphi approach to Attain consensus in methodology of local regional therapy for peritoneal surface malignancy. J Surg Oncol (2008) 0.77
The role of hyperthermic intraperitoneal chemotherapy (HIPEC) and isolated perfusion (ILP) interventions in sarcoma. J Surg Oncol (2014) 0.77
Stop Flow in abdominal and pelvic cancer relapses. Front Biosci (2006) 0.77
Is the Combination of Distal Pancreatectomy and Cytoreductive Surgery With HIPEC Reasonable?: Results of an International Multicenter Study. Ann Surg (2016) 0.77
Prospective Registry On Mesothelioma Peritonei Treatment (PROMPT): study design and rationale. Tumori (2012) 0.76
Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single center. In Vivo (2007) 0.76
Colorectal Cancer Peritoneal Metastases: Second-look Laparotomy, Prophylactic HIPEC, or Both? Ann Surg (2016) 0.75
Circulating tumor markers: predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei. J Surg Oncol (2013) 0.75
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in a patient with peritoneal mesothelioma and HIV infection. Tumori (2010) 0.75
MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study. Melanoma Res (2017) 0.75
Tubular dysfunction after peritonectomy and chemohyperthermic treatment with cisplatin. In Vivo (2007) 0.75
Pilot study of adjuvant hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer at high risk for the development of peritoneal metastases. Tumori (2013) 0.75